• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Another Sleeping Pill on the Market: Merck’s Belsomra

Another Sleeping Pill on the Market: Merck’s Belsomra

September 1, 2014
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Short Description:

Another Sleeping Pill on the Market: Merck’s Belsomra

Background:

The US Food and Drug Administration (FDA) last month approved Merck’s new insomnia drug, Belsomra, the first in a new class of hypnotics termed “orexin antagonists.” If you’ve never heard of orexin, put on your seat belts, because you’ll be getting a crash course from your local drug reps. Also known as hypocretins, orexins are chemicals discovered in 1998 that are secreted in the hypothalamus, and which normally function to keep us awake. It was only a matter of time before orexin blockers were developed, and Merck won the race. (TCPR will have a full take on Belsomra in our next issue.)

Generically known as suvorexant, Belsomra beats placebo in getting people to sleep, but it can cause next-day drowsiness and impaired driving. As a result, the FDA said that no more than one pill should be taken each night and the dose should not exceed 20 mg. The FDA is requiring that Merck continue to study next-day driving performance of patients taking the sedative. Belsomra is expected to be available in late 2014 or early 2015.

Impaired driving the morning after taking a sleeping pill is a phenomenon that has been recognized for more than a decade. The FDA first took action in January 2013 when it recommended cutting the dose of zolpidem (Ambien) by half, from 10 mg to 5 mg for immediate-release formulas, and from 12.5 mg to 6.25 mg for controlled-release formulas.

Results for Belsomra showed impaired driving in patients who took 20 mg. The FDA approved the drug in 5, 10, 15, and 20 mg doses. Merck had originally proposed that non-elderly adults start on 20 mg and increase to 40 mg if needed.

The recommended dose of Belsomra is 10 mg within 30 minutes of going to bed and patients then need to wait at least seven hours and be cautious about next-day driving.

The FDA also recommended that Belsomra be listed as a controlled substance because it can be addictive and has the potential to be abused (http://1.usa.gov/1qRWmaY). The Drug Enforcement Administration (DEA) is proposing that the drug be given a Schedule IV designation, the same as medications such as alprazolam (Xanax), clonazepam (Klonopin), and Ambien.

General Psychiatry
KEYWORDS news_of_note sleep_disorders
www.thecarlatreport.com
Issue Date: September 1, 2014
SUBSCRIBE NOW
Table Of Contents
Step Right Up—Meaningful Use Incentives are Adding Up
Op-Ed: Maintenance of Certification—Is it safe to opt out?
Maintenance of Certification: What You Need to Know
Using Transcranial Magnetic Stimulation (TMS) in Your Practice
Mood Stabilizer Plus Antidepressant May Protect Against Mania
CBT Moderately Effective in Improving Quality of Life for Anxiety Disorders
Another Sleeping Pill on the Market: Merck’s Belsomra
Should We Share Therapy Notes with Our Patients?
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.